Evidence map›Paper›PMID 36407262›Full record

ReviewCureus2022

Iron Deficiency in Heart Failure: What Do We Know So Far?

Amr Elkammash, Rasha M Farahat, Aya Al Sattouf, Julius Lenaerts, Khin Yadanar Maung, Aayesha Khatri

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Amr ElkammashCardiology, Royal Papworth Hospital NHS Foundation Trust, Cambridge, GBR.
Rasha M FarahatMedicine, West Suffolk NHS Foundation Trust, Suffolk, GBR.
Aya Al SattoufMedicine, West Suffolk NHS Foundation Trust, Suffolk, GBR.
Julius LenaertsInternal Medicine, West Suffolk NHS Foundation Trust, Suffolk, GBR.
Khin Yadanar MaungInternal Medicine, West Suffolk NHS Foundation Trust, Suffolk, GBR.
Aayesha KhatriIntensive Care Unit, King's College NHS Foundation Trust, London, GBR.
King's College Hospital NHS Foundation Trust · GBWest Suffolk NHS Foundation Trust · GBPapworth Hospital NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron is vital for multiple biological processes in the human body. Heart failure (HF) patients are at a high risk of becoming iron deficient. Iron deficiency is a marker of severe HF and an ominous sign of poor outcomes. Iron deficiency can be absolute (low iron stores) or functional (improper functioning in the metabolic processes). The European Society of Cardiology recommends routine screening of iron stores in HF patients using ferritin and transferrin saturation. It advises iron replacement in deficient patients irrespective of the presence of anemia. Iron replacement improved HF symptoms, exercise capacity, and quality of life in deficient patients. It alleviates their disordered breathing during sleep. Therefore, the treatment of iron deficiency is an important target in managing HF. Oral iron is not effective in repleting iron stores in HF patients. Intravenous iron is an effective way to replenish iron stores in this cohort.

Indexed as

anemiadeficiencyferric carboxymaltoseheart failureheart failure with preserved ejection fraction (hfpef)heart failure with reduced ejection fractionironmetabolism

Identifiers

PMID36407262
PMCPMC9664420
OpenAlexW4306353415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.